Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says

MT Newswires Live

Dec 11, 2025

Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.

Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.

Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products "multi-billion-dollar opportunities."

The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.

Price: 19.59, Change: +1.15, Percent Change: +6.21

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590534392"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590534392\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590534392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 01:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590534392","market":"sh","top_or_hot":-1,"title":"Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-11 01:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) biggest catalyst moving forward is the read-through from competitor <a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.</p><p>Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.</p><p>Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"</p><p>The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.</p><p>Price: 19.59, Change: +1.15, Percent Change: +6.21</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590534392","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590534392","pubTimestamp":1765388276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","OPY":"奥本海默控股","DYN":"戴纳基","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4127":"投资银行业与经纪业","RNA":"Avidity Biosciences, Inc."},"translate_title":"奥本海默表示，Dyne Therapeutics最大的催化剂是Avidity Biosciences 2026年下半年的DM1读数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1.5,"RNA":1.5,"DYN":1.5},"content_text":"Dyne Therapeutics' (DYN) biggest catalyst moving forward is the read-through from competitor Avidity Biosciences (RNA) phase 3 myotonic dystrophy type 1 readout in H2 of 2026 to further inform its probability of success in DM1, Oppenheimer said in a Wednesday note.Along with this, Dyne Therapeutics' stock is expected to see upside from positive regulatory updates on the company's Duchenne Muscular Dystrophy program throughout 2026 and advancement of the Facioscapulohumeral Muscular Dystrophy program, Oppenheimer said.Despite increased competition in DMD, the brokerage said that high unmet need, along with pricing flexibility, renders the company's products \"multi-billion-dollar opportunities.\"The firm upgraded its rating on Dyne Therapeutics to outperform from perform and raised its price target to $40 from $11.Price: 19.59, Change: +1.15, Percent Change: +6.21","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}